Comparing Prostate Specific Antigen Triggers for Intervention in Men With Stable Prostate Cancer on Active Surveillance (Q85040010)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

title

Comparing prostate specific antigen triggers for intervention in men with stable prostate cancer on active surveillance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

Comparing Prostate Specific Antigen Triggers for Intervention in Men With Stable Prostate Cancer on Active Surveillance (English)

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

14 July 2024

7

Laurence Klotz

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Andrew Loblaw

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

Liying Zhang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

Adam Lam

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

Robert Nam

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

Alexandre Mamedov

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

Danny Vesprini

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20846681

14 July 2024

publication date

17 September 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

full work available at URL

14 February 2020

https://api.elsevier.com/content/article/PII:S0022534710040231?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

https://api.elsevier.com/content/article/PII:S0022534710040231?httpAccept=text/plain

14 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

http://www.jurology.com/doi/pdf/10.1016/j.juro.2010.06.101

14 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

14 July 2024

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

volume

184

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

1942-1946

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

14 February 2020

cites work

2

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

14 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Contemporary trends in low risk prostate cancer: risk assessment and treatment

14 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry

14 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort

14 July 2024

7

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005

14 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial

14 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial

14 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

14 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer

14 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Predicting the probability of deferred radical treatment for localised prostate cancer managed by active surveillance

14 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Expectant management of prostate cancer with curative intent: an update of the Johns Hopkins experience

14 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience

14 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Active surveillance for prostate cancers detected in three subsequent rounds of a screening trial: characteristics, PSA doubling times, and outcome

14 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: Results from the European randomized study of screening for prostate cancer, Sweden section

14 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Temporarily deferred therapy (watchful waiting) for men younger than 70 years and with low-risk localized prostate cancer in the prostate-specific antigen era

14 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Modeling prostate specific antigen kinetics in patients on active surveillance

14 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Screening and prostate-cancer mortality in a randomized European study

14 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

14 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.JURO.2010.06.101

14 July 2024

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20846681 AND SRC:MED&resulttype=core&format=json

14 February 2020

1 reference